ABSTRACT The objective of this analysis was to assess reactogenicity profile differences between a protein- and mRNA-based COVID-19 vaccine in participants who had previously received ≥2 doses of an mRNA-based vaccine in a real-world, double-blinded, randomized, controlled trial. In the BEEHIVE/NCT06065176 trial (Clini...
Sarang K. Yoon, Andrew L. Phillips, Hong-Wei Zhao et al.· Human Vaccines & Immunothera...· 0 citations
Nirsevimab and maternal RSV vaccination were effective against RSV-associated ED encounters and hospitalization among infants in their first RSV season, and monitoring infant RSV immunization effectiveness remains important.
A. Payne, S. Battan-Wraith, S. E. Reese et al.· Pediatrics· 0 citations
The results suggest that both protein-based and mRNA vaccines are well-tolerated and significantly reduce the risk of symptomatic SARS-CoV-2 infections.
Sarang K. Yoon, Andrew L. Phillips, S. Battan-Wraith et al.· Vaccine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.